Response to comment on: Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy
Sir, We would like to thank the authors for their interest and comments on the article "Dramatic response to intravitreal Bevacizumab in Hypertensive Retinopathy" [1, 2] and address their queries as follows:
As mentioned by the authors, fellow eye effect of unilateral intravitreal Bevacizumab is controversial and the factors on which it depends are unknown. [3] It is therefore difficult to predict the effect on the fellow eye after unilateral intravitreal Bevacizumab. We noticed a significant reduction of intraretinal and subretinal fluid in both the eyes at 1 week after unilateral intravitreal Bevacizumab injection, while the blood pressure (BP) was still not well controlled. Since the patient was started on oral steroids 1 month back (as per advice of the treating nephrologist) and developed severe hypertensive retinopathy during this period, it is unlikely that systemic steroids would have contributed toward resolution of intraretinal and subretinal fluid. All these factors point toward the effect of intravitreal Bevacizumab on the fellow eye. Nevertheless, it is difficult to exclude the additional effect of hypertension control at 1 month on the resolution of macular edema.
The pre-injection central subfield macular thickness (CST) was 695 microns in OD and 591 microns in OS. At 1-month post injection, it was 301 microns in OD and 282 microns in OS.
We agree with the authors that intravitreal Bevacizumab may cause dysregulation of BP, especially in severely hypertensive patients. [4] However, the rise in BP after intravitreal Bevacizumab is usually mild and is considered to be safe even in hypertensive patients. [5, 6] Furthermore, our patient was under close observation in our institution's nephrology and cardiology departments and due clearance had been obtained prior to the injection.
The dramatic anatomical and functional response to intravitreal Bevacizumab in our patient reinforces that this maybe a viable option to avoid irreversible vision loss from macular edema in hypertensive retinopathy. Collaboration with cardiology and nephrology departments for BP control and subsequent monitoring is warranted in such patients.
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Sir,
We read with interest the case report [1] on the resolution of bilateral subfoveal fluid and disc edema due to hypertensive retinopathy (HTNR) after unilateral intravitreal bevacizumab. We want to discuss few points. As the primary cause of HTNR is hypertension, the adequate control of hypertension is the most important intervention. Without the adequate control of BP, any intervention including intravitreal anti-vascular endothelial growth factor (VEGF) agents may not be considered. Though bevacizumab has been considered as a "wonder drug," it carries a rare but devastating risk of blindness due to endophthalmitis. [2] However, in the clinical setting even after control of hypertension, the subfoveal fluid may not resolve and the patient may want earlier visual rehabilitation. Salman [3] used intravitreal bevacizumab in 12 cases of persistent HTNR despite control of hypertension for 1 month and noted stabilization and improvement of vision in all cases. This paper [1] also adds to the evidence [4, 5] that anti-VEGF agents may be helpful in HTNR. The exact role of anti-VEGF agents in HTNR needs further exploration, but these agents may add to the armamentarium to treat the cases of HTNR with subfoveal fluid which do not resolve despite good systemic control.
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